Tilray's exclusive position in Portugal's medical marijuana market is notable, but the high cost of its product and the limited conditions for prescription may restrict domestic sales growth. The contrast between the large volume of exports and minimal domestic sales highlights regulatory and market challenges that could impact Tilray's performance in the short term. However, the overall impact on stock price is uncertain due to the complexity of market dynamics and regulatory environments.